CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病对过继性 T 细胞治疗应答的悖论
英文原题：The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.
查看英文原题
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自从认识到异基因移植物抗白血病效应以来，急性髓系白血病（AML）已被确认为一种T细胞可靶向的恶性肿瘤，但现代免疫治疗形式的成功比预期要慢。在本期中，我们讨论了近期报道所揭示的T细胞治疗AML的生物学障碍，包括Tin及其同事对AML抵抗T细胞介导杀伤的机制性见解。参见Tin等人的相关文章，第217页。
展开英文摘要原文
Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In this issue, we discuss the biological barriers to the treatment of AML with T-cell therapy revealed by recent reports, including mechanistic insights into AML resistance to T cell-mediated killing by Tin and colleagues. See related article by Tin et al., p. 217.
论文信息
- 作者
- Fry TJ
- 单位
- Gates Institute; Pediatrics and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.United States
- 期刊
- Blood cancer discovery2025 May 5
- 原文标识
- PubMed 40237696 · DOI 10.1158/2643-3230.BCD-25-0017
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →